Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005959 | 0.90 | MTNR1A (0.52) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| Acetamide SCHEMBL15661095 | 0.89 | MTNR1A (0.58) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL4749238 | 0.88 | MTNR1A (0.75) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL31558766 | 0.88 | MTNR1A (0.75) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL3914252 | 0.87 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL30692247 | 0.87 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL28723358 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL4749622 | 0.85 | MTNR1A (0.63) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL15509773 | 0.85 | MTNR1A (0.64) | MTNR1AMTNR1BHTR2CHTR2BNQO2 | |
| SCHEMBL8017007 | 0.83 | MTNR1A (0.76) | MTNR1AMTNR1BHTR2CHTR2BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2909166-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014096373-A1 | PROCESS FOR PREPARARING N-(2-(7-METHOXY-1-NAPHTHALENYL)ETHYL) ACETAMIDE AND SOLID FORMS THEREOF | LABORATORIOS LESVI, S. L. (ES) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-5449690-A | Antihypercholesterol anf melatonin antagonist | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5449689-A | Treating melatoninergic system disorders | ADIR ET COMPAGNIE (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5389683-A | Useful in treating or preventing a disorder of the melatoninergic system | ADIR ET COMPAGNIE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5385944-A | Naphthylethylureas and naphthylethylthioureas | ADIR ET COMPAGNIE (FR) | 1995-01-31 | — | — | US | disclosed |
| US-5318994-A | Treating melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1994-06-07 | — | — | US | disclosed |
| US-5225442-A | Melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1993-07-06 | — | — | US | disclosed |
| US-5194614-A | COMPOUNDS HAVING A NAPHTHALENE STRUCTURE | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | MTNR1A 845/4885MTNR1B 513/4885HTR2C 16/4885 |
| US-20080280991-A1 | SUBSTITUTED NAPHTHALENES | MTNR1A, MTNR1B, TPH1 | MTNR1A 1/4885MTNR1B 2/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.